Patent Examiner Charanjit Aulakh
Art Unit 1621 · Heterocyclic Drug Compounds & Pharmaceutical Compositions · Tech Center 1600 · 495 applications filed 2021–2026
Charanjit Aulakh is a USPTO patent examiner in Art Unit 1621 (Heterocyclic Drug Compounds & Pharmaceutical Compositions) with 495 applications from filing years 2021–2026. Examiner Aulakh's allowance rate is 77.1%, below the 82.9% USPTO average for applications filed in the same years. The examiner ranks harder than 64% of examiners. In 2021, decided applications with an examiner interview were allowed 25.1 percentage points more often than those without.
Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology
Overview
FreeExaminer details
- Art unit1621 · Heterocyclic Drug Compounds & Pharmaceutical Compositions
- Title / gradePrimary Patent Examiner · GS-14
- Service30 years
- PhoneOn each office action
- Email[email protected]
- In USPTO recordsAULAKH, CHARANJIT
Examiner Aulakh can allow an application without a supervisory sign-off.
How to improve your odds with Examiner Aulakh
- The data favors an interview. Interviewed cases were allowed more often in all 4 measured years, by 14.7 to 28.5 points.
- The timeline tracks the norm. First office action averages 609 days vs the 617-day USPTO norm.
- Expect a §112. Definiteness & disclosure is the most-issued rejection (250), and applicants overcame it 71.1% of the time.
- The data favors an RCE here. Cases with an RCE were allowed more often in all 4 measured years, by 1.7 to 32.6 points.
Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.
Rejection patterns & how they get overcome
FreeOf the 99 winning responses to Examiner Aulakh's §112 rejections that Boundly has classified, 73 (74%) amended the claims and argued, 22 amended without arguing, and 4 argued without amending. Each winning response, with its arguments and claim amendments, is in the file wrapper.
Just got an office action from Examiner Aulakh?
Draft your response with Examiner Aulakh's record and Art Unit 1621's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See office action responses in AI Studio.
Trends
| Year | Interview rate | Allowance w/ interview | Allowance w/o | Delta |
|---|---|---|---|---|
| 2024 | 17.3% | 100.0% | 79.2% | +20.8pp |
| 2023 | 22.9% | 95.7% | 81.0% | +14.7pp |
| 2022 | 17.8% | 95.2% | 66.7% | +28.5pp |
| 2021 | 26.7% | 90.6% | 65.5% | +25.1pp |
RCE behavior
Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Aulakh.
| Year | RCE rate | Allowance w/ RCE | Allowance w/o | Delta |
|---|---|---|---|---|
| 2024 | 8.2% | 100.0% | 82.8% | +17.2pp |
| 2023 | 10.0% | 85.7% | 84.0% | +1.7pp |
| 2022 | 14.4% | 100.0% | 67.4% | +32.6pp |
| 2021 | 15.0% | 83.3% | 70.3% | +13.0pp |
Recent outcomes
Free🔒 Case detail for members| App # | Title | Outcome | OAs | Arguments & redline |
|---|---|---|---|---|
| 18/262914 | 5-Fluoro-4-Imino-3-Methyl-1-Tosyl-3,4-Dihydropyrimidin-2(1H)-One for Controlling Plant Diseases | Patented | 1 | 🔒 View |
| 19/419278 | New Salt Forms of Sabcomeline | Patented | 2 | 🔒 View |
| 18/551214 | Treatment of Sickle Cell Anaemia | Patented | 2 | 🔒 View |
| 18/634083 | Tetradentate Platinum and Palladium Complexes Based on Biscarbazole and Analogues | Patented | 5 | 🔒 View |
Art Unit 1621 technology
Frequently asked questions
What is Examiner Charanjit Aulakh's allowance rate?
Is Examiner Aulakh a hard examiner?
Do examiner interviews help with Examiner Aulakh?
What is Examiner Aulakh's most common rejection?
Is an RCE worth filing with Examiner Aulakh?
How long until the first office action from Examiner Aulakh?
How do I contact Examiner Charanjit Aulakh?
Put Examiner Aulakh's data to work on your next response.
Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.